Introduction
Prostate cancer remains one of the most commonly diagnosed malignancies among men worldwide, presenting substantial heterogeneity in incidence, mortality, and survival across geographic regions, racial groups, and socioeconomic strata. This review synthesizes the latest epidemiological evidence from authoritative sources including the Global Burden of Disease (GBD) Study 2021–2023, GLOBOCAN 2022, and national cancer registries to provide a comprehensive overview of global and regional disease burden, temporal trends over the past decade, demographic and risk-factor stratifications, and quality-of-life impacts.
Global Burden
The most recent global estimates from GLOBOCAN 2022 indicate that prostate cancer is the world's second most frequent cancer among men, with approximately 1.5 million new cases and 397,000 deaths reported globally in 20221112. According to the GBD 2021 framework, the global age-standardized incidence rate (ASIR) was 34.05 per 100,000 men, with an age-standardized prevalence rate (ASPR) of 260.05 per 100,0001. The age-standardized mortality rate (ASMR) stood at 12.63 per 100,000, yielding a global disability-adjusted life year (DALY) rate of 217.83 per 100,0001. Prostate cancer ranks among the leading causes of cancer-related mortality in men, particularly in regions with aging populations.
The disease burden exhibits a pronounced age gradient, with heavier burden after age 70, mortality peaking in the 80–84 age group, and prevalence peaking in the 75–79 age group1. ARIMA-based projections to 2040 suggest continued rises in prevalence (266.23 per 100,000) and incidence (35.21 per 100,000), but declining mortality (9.11 per 100,000) and DALYs (176.16 per 100,000), reflecting anticipated improvements in treatment and early detection1.
Regional Patterns
Geographic disparities in prostate cancer burden are striking. Age-standardized incidence rates varied approximately 13-fold globally in 2022, with Northern Europe reporting the highest ASIR at 82.8 per 100,000 men and South-Central Asia the lowest at 6.4 per 100,0001. Mortality rates demonstrated a 9.5-fold variation, with Southern Africa exhibiting the highest ASMR at 29.7 per 100,000 and South-Central Asia the lowest at 3.1 per 100,0001.
Regional patterns stratified by Sociodemographic Index (SDI) reveal that high SDI regions report the highest prevalence (ASPR 612.57 per 100,000) and incidence (ASIR 70.92 per 100,000)1. High-Income North America demonstrates peak rates globally, with ASPR of 910.62 per 100,000 and ASIR of 101.92 per 100,0001. Australia, New Zealand, Brazil, and several Caribbean and Northern European nations also report elevated incidence rates1.
In contrast, low SDI regions paradoxically bear the highest mortality burden (ASMR 16.8 per 100,000), with Southern Sub-Saharan Africa reporting ASMR of 44.25 per 100,000 and DALY rate of 774.4 per 100,000—the highest geographic burden globally1. This disproportionate mortality despite lower incidence reflects limited access to PSA screening, delayed diagnosis, advanced disease stage at presentation, and constrained treatment resources. Among BRICS countries, Brazil leads in incidence (ASIR 55.029 per 100,000) and prevalence (ASPR 372.511 per 100,000), while South Africa faces the highest mortality (ASMR 42.241 per 100,000) and DALY burden (666.085 per 100,000)2.
These regional disparities are driven by multiple factors including PSA screening intensity, diagnostic capacity, population age structure, genetic ancestry, life expectancy, and healthcare system maturity. High-income nations with widespread screening detect more indolent cancers, inflating incidence while reducing mortality through early intervention, whereas resource-limited settings diagnose predominantly symptomatic, advanced-stage disease.
Temporal Trends
Temporal analysis from 1990 to 2021 reveals divergent trajectories. Globally, prevalence increased by 19% and incidence by 4%, while mortality declined by 23% and DALYs decreased by 21%1. During the most recent 5-year period examined (approximately 2017–2022), incidence rates increased in 11 of 50 countries studied, with annual increases ranging from 0.7% (Scotland) to 10.0% (Poland), while rates decreased in 15 countries (0.7% in New Zealand to 6.2% in Israel) and stabilized in 24 countries1.
Mortality trends showed more consistent improvement: mortality rates declined in 38 of 59 countries (0.6–7.8% annually), predominantly in Europe, Oceania, and Latin America/Caribbean, reflecting treatment advances and earlier detection. However, mortality increased in 9 countries (0.5–7.9% annually), predominantly in Africa, Asia, Latin America/Caribbean, and Central/Eastern Europe1.
Regional temporal trends highlight epidemiological transitions. Eastern Europe exhibited the fastest ASIR increase among regions (1.47-fold from 1990–2021), with Poland showing 10.0% annual incidence growth in recent years1. Low-middle SDI regions demonstrated the fastest relative increase in ASIR (0.68-fold) and DALYs (0.24-fold) from 1990–20211. In Asia, incidence continues to rise 4.0–5.0% annually in China, India, and Thailand, while mortality decreased 1.5–5.2% annually in Japan and the Republic of Korea1. South Korea demonstrated the largest relative increase in ASPR globally (4.04-fold from 1990–2021)1.
These trends reflect evolving PSA screening practices, adoption of MRI-targeted biopsy, active surveillance for low-risk disease, and treatment advances including androgen-deprivation therapy and novel systemic agents. The US SEER data and European EUROCARE registries document incidence peaks coinciding with PSA screening dissemination in the 1990s–2000s, followed by declines as screening guidelines emphasized shared decision-making and risk stratification.
Demographics and Risk Factors
Age and Race/Ethnicity
Prostate cancer incidence rises steeply with age, with median diagnosis occurring in the seventh decade. Men of African ancestry face disproportionate burden: in the United States, Black men experience higher incidence and mortality than White men, with substantial survival differentials6. A prospective cohort study of 1,417 prostate cancer cases in Black men and 28,845 in White men demonstrated that many dietary, nutrient, and health-related risk factors associated with risk in predominantly non-Hispanic White men were not associated with risk in Black men, underscoring population-specific etiologic heterogeneity6. Height showed opposite associations by race (positive in White men, inverse in Black men; p_interaction = 0.01)6.
Genetic and Familial Risk
The HOXB13 G84E mutation confers substantially elevated risk, with a meta-analysis yielding a pooled relative risk of 3.43 (95% CI 2.78–4.23)4. However, absolute risk by age 85 varies dramatically—from 60% for mutation carriers with no family history to 98% for those with two relatives diagnosed at young ages, compared with 15% for noncarriers4. Birth cohort significantly modifies risk: men born in 1930 or later carrying the mutation had an RR of 5.96 (95% CI 4.01–8.88), nearly double that of earlier cohorts (RR 3.09)4. HOXB13 G84E accounts for approximately 3.6% of excess familial prostate cancer risk in the UK population4. BRCA1/2 mutations and polygenic risk scores further stratify individual susceptibility.
Modifiable Risk Factors
Evidence for modifiable risk factors remains largely inconclusive. The GBD 2021 analysis identified smoking and high calcium diet as associated risk factors1. A systematic review of 39 reports evaluating drugs, metabolic diseases, and dietary factors (2003–2017) found only low-quality evidence for modest protective effects of metformin, aspirin, and statins, and associations with diabetes and obesity5. Specific dietary intakes, physical activity, and prostatitis showed insufficient evidence or no consistent effect5. Screening-related overdiagnosis and lead-time bias represent major contextual "risk" factors for observed incidence, particularly in high-income nations with widespread PSA testing.
Disease Burden and Quality of Life
Mortality and Survival
Global mortality burden stands at 397,000 deaths annually, with five-year relative survival varying substantially by region and stage at diagnosis. CONCORD-3 data (2000–2014) provide country- and stage-specific survival estimates, though more recent updates are needed27. Survival has improved in high-income nations due to earlier detection and multimodal therapy, but remains poor in resource-limited settings where advanced-stage disease predominates.
DALYs and YLL vs YLD
The global DALY rate of 217.83 per 100,000 reflects substantial morbidity and premature mortality1. Temporal trends show DALYs declining 21% from 1990 to 2021 globally, with projected further decline to 176.16 per 100,000 by 20401. Regional variation is pronounced: low SDI regions bear DALY rates of 294.26 per 100,000, while Southern Sub-Saharan Africa reports 774.4 per 100,0001. Although specific YLL versus YLD decomposition data were not fully detailed in the retrieved materials, mortality-driven DALYs (YLL) predominate given the age distribution and case-fatality profile of prostate cancer. The GBD 2023 interactive tools provide granular YLL and YLD estimates accessible via IHME VizHub92425.
Quality of Life
Health-related quality of life (HRQoL) is profoundly affected by prostate cancer treatment. Validated instruments including the Expanded Prostate Cancer Index Composite (EPIC), EORTC QLQ-C30 with prostate-specific module QLQ-PR25, and FACT-P are the predominant tools used in clinical trials and survivorship studies1723. A systematic review of RCTs (2012–2019) found that 43.6% met high-quality criteria for patient-reported outcome (PRO) assessment, with the most frequently reported domains being overall quality of life and sexual, urinary, and bowel function17.
The EUPROMS cross-sectional survey of 2,943 European prostate cancer patients (2019) reported an overall sexual function score of 27/100, with the lowest scores (15/100) among men treated with combined surgery and radiotherapy21. Urinary incontinence was most affected by surgery, while fatigue and insomnia were highest among men receiving radiotherapy or chemotherapy21. Prospective cohort data from robot-assisted laparoscopic prostatectomy patients demonstrate that global and physical QoL typically recover to baseline by 3–12 months, but incontinence aid use, treatment-related symptoms, and sexual functioning remain significantly worse than preoperative levels at 24 months19. Long-term survivors (5–10 years post-diagnosis) treated with nerve-sparing radical prostatectomy report statistically higher sexual activity than those undergoing non-nerve-sparing approaches, though differences are clinically meaningful only in older men18.
Limitations
Key limitations include registry completeness and cause-of-death coding accuracy, particularly in low- and middle-income countries. PSA screening variability across and within nations complicates incidence trend interpretation, as screening dissemination inflates detection of indolent cancers (overdiagnosis) and introduces lead-time bias. Stage definitions differ across registries, and population age structure influences crude rates. Risk-factor evidence derives predominantly from observational studies with heterogeneous exposure definitions and insufficient control for PSA screening impact5. Racial and ethnic minority populations remain under-represented in cohort studies, limiting generalizability of risk-factor associations6. Quality-of-life data reflect selected clinical trial populations and may not represent community practice or resource-limited settings.
Implications and Conclusion
Prostate cancer represents a major global health challenge with marked geographic, demographic, and socioeconomic disparities. High-income regions face detection-driven incidence inflation requiring judicious screening and active surveillance to mitigate overtreatment, while resource-limited regions confront disproportionate mortality from late-stage disease, demanding investment in early detection infrastructure and treatment access. Screening guidelines increasingly emphasize shared decision-making, MRI-targeted biopsy, and biomarker-informed risk stratification. Targeted outreach to men of African ancestry and those with familial/genetic predisposition is warranted. Survivorship care planning must address persistent urinary, sexual, and bowel dysfunction. Future research priorities include robust risk-factor studies in diverse populations, population attributable fraction quantification for modifiable exposures, and equitable access to precision diagnostics and multimodal therapy globally.